FIELD: biotechnology; medicine.
SUBSTANCE: present invention relates to biotechnology and medicine, namely to a monoclonal antibody that specifically binds to human CEACAM1. Present invention also discloses a polynucleotide encoding said antibody, a plasmid for its production, a pharmaceutical and diagnostic composition for the treatment of a malignancy characterized by the overexpression of CEACAM1, and for the detection of human CEACAM1, respectively. Method for preventing or treating a disease or disorder associated with the expression, activation or function of human CEACAM1, method of immunostimulation, method of inhibiting the interaction of human CEACAM1 with CEACAM1, as well as methods for diagnosing a malignant tumor expressing CEACAM1 are disclosed.
EFFECT: present invention allows to increase the specificity of antibodies against human CEACAM1.
16 cl, 20 dwg, 1 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS CONTAINING ANTI-SEAMS 1 AND ANTI-PD ANTIBODIES FOR CANCER THERAPY | 2014 |
|
RU2697522C1 |
| CEACAM1 ANTIBODIES AND METHODS FOR USE THEREOF | 2010 |
|
RU2598710C2 |
| BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47 | 2019 |
|
RU2798246C2 |
| ANTIBODIES SPECIFIC TO HUMAN POLIOVIRUS RECEPTOR (PVR) | 2017 |
|
RU2756275C2 |
| ANTIBODIES AGAINST PD-1 AND THEIR USE | 2018 |
|
RU2788616C2 |
| ANTIBODIES SPECIFIC TO HUMAN NECTIN-4 | 2019 |
|
RU2825839C2 |
| VERSIONS OF HUMANIZED IMMUNOMODULATORY MONOCLONAL ANTIBODIES | 2012 |
|
RU2604814C2 |
| ANTI-PD-L1 ANTIBODY AND ITS USE | 2020 |
|
RU2783685C2 |
| NOVEL ANTI-PD-L1 ANTIBODIES | 2016 |
|
RU2736151C2 |
| HUMAN NECTIN-2 SPECIFIC ANTIBODIES | 2020 |
|
RU2820275C2 |
